Novo Nordisk (NVO) stock surged Tuesday after the Swiss drugmaker said its weight-loss drug reduced the risk of cardiovascular events for overweight adults and those with obesity.
X
The news benefits the entire class of weight-loss drugs, including Eli Lilly’s Mounjaro. Novo studied its drug Wegovy over five years in more than 17,000 adults with cardiovascular disease but not diabetes.
Patients who received Wegovy were 20% less likely to experience a major cardiovascular event, like a heart attack or stroke, than those who received a placebo.
“Insurance plans still need to agree to reimburse for these drugs for certain patient types, but this (study’s) results should open the door for this possibility, assuming Novo’s full data is positive,” Edward Jones analyst John Boylan said in a note to clients.
In response, Novo Nordisk stock rocketed 16.3% near 187.70 in afternoon…
